Barateau Lucie, Diab Joseph, Thobois Ophélie, Chenini Sofiene, Béziat Séverine, Jaussent Isabelle, Dauvilliers Yves
Sleep-Wake Disorders Unit, Department of Neurology, Gui-de-Chauliac Hospital, CHU Montpellier, Montpellier, France.
National Reference Centre for Orphan Diseases, Narcolepsy, Idiopathic Hypersomnia, and Kleine-Levin Syndrome, Montpellier, France.
Eur J Neurol. 2025 Jul;32(7):e70259. doi: 10.1111/ene.70259.
Kleine-Levin Syndrome (KLS) is a neurological disorder of unknown pathophysiology. It is characterized by relapsing-remitting episodes of hypersomnia, with cognitive symptoms and behavioral disturbances. The diagnosis relies on clinical criteria, which require further standardization. Our main objective was to better phenotype and systematically quantify the severity and impact of cognitive and behavioral symptoms, hypersomnolence and dysautonomia in a well-characterized population of KLS patients.
Forty-three consecutive KLS patients diagnosed in a National Reference Center for Rare Hypersomnias underwent a standardized clinical and polysomnographic evaluation and completed validated questionnaires with their relatives. The Behavioral Dysexecutive Syndrome Inventory (BDSI) assessed their behavior during most episodes. The Idiopathic-Hypersomnia Severity Scale (IHSS) assessed different hypersomnolence components (inertia, sleepiness, prolonged sleep), and the Scale for Outcomes in Parkinson's Disease-Autonomic (SCOPA-AUT) assessed dysautonomia. The latter two scales were completed twice to differentiate symptoms during and between episodes.
During symptomatic periods, behavioral changes were observed in all BDSI domains, more than half of patients showing reduced activities and apathy, anticipation-organization-initiation difficulties, disinterest, irritability-aggression, perseveration-stereotypies, and sexual or eating disorders. IHSS scores were severe and higher during episodes (42.6 ± 5.8 vs. 15.6 ± 9.8, p < 0.0001), and each item higher. The SCOPA-AUT scores were higher during episodes (12.1 ± 8.5 vs. 8.5 ± 8.2, p = 0.0001), particularly in the cardiovascular, pupillomotor, and thermoregulation domains.
Our findings suggest the relevance of the BDSI for the evaluation of dysexecutive behavioral symptoms in KLS. The IHSS would be useful for phenotyping hypersomnolence and the SCOPA-AUT for assessing dysautonomia during episodes. Future studies could combine the BDSI with imaging and other biomarkers to explore the neuroanatomical correlates of this enigmatic disorder.
克莱恩-莱文综合征(KLS)是一种病理生理学不明的神经系统疾病。其特征为发作性睡病的复发-缓解发作,伴有认知症状和行为障碍。诊断依赖于临床标准,而这些标准需要进一步规范。我们的主要目标是在特征明确的KLS患者群体中更好地表征并系统量化认知和行为症状、嗜睡及自主神经功能障碍的严重程度和影响。
在国家罕见发作性睡病参考中心连续诊断的43例KLS患者接受了标准化临床和多导睡眠图评估,并与其亲属一起完成了经过验证的问卷。行为执行综合征量表(BDSI)评估了他们在大多数发作期间的行为。特发性发作性睡病严重程度量表(IHSS)评估了不同的嗜睡成分(惰性、困倦、睡眠时间延长),帕金森病自主神经功能障碍结局量表(SCOPA-AUT)评估了自主神经功能障碍。后两个量表完成了两次,以区分发作期间和发作间期的症状。
在有症状期间,BDSI所有领域均观察到行为变化,超过一半的患者表现出活动减少和冷漠、预期-组织-启动困难、兴趣缺乏、易怒-攻击性、持续性-刻板行为以及性或饮食障碍。IHSS评分在发作期间严重且更高(42.6±5.8对15.6±9.8,p<0.0001),且各项更高。SCOPA-AUT评分在发作期间更高(12.1±8.5对8.5±8.2,p=0.0001),特别是在心血管、瞳孔运动和体温调节领域。
我们的研究结果表明BDSI对于评估KLS中执行功能障碍行为症状具有相关性。IHSS对于发作性睡病的表型分析有用,SCOPA-AUT对于评估发作期间的自主神经功能障碍有用。未来的研究可以将BDSI与影像学和其他生物标志物结合起来,以探索这种神秘疾病的神经解剖学相关性。